Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
QuintilesIMS
Cerilliant
Mallinckrodt
Harvard Business School
Covington
US Department of Justice
Express Scripts

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,969,566

« Back to Dashboard

Which drugs does patent 8,969,566 protect, and when does it expire?


Patent 8,969,566 protects AVYCAZ and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 8,969,566

Title:Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), ##STR00001## including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
Inventor(s): Ronsheim; Melanie Simone (Port Jefferson, NY), Racha; Saibaba (Smithtown, NY), Lawton; Graham Richard (Smithtown, NY), Zhou; Shao Hong (Commack, NY), Kalyan; Yuriy B. (Staten Island, NY), Golden; Michael (Macclesfield, GB), Milne; David (Macclesfield, GB), Telford; Alexander (Macclesfield, GB), Cherryman; Janette (Macclesfield, GB), Boyd; Alistair (Cheshire, GB), Phillips; Andrew (Macclesfield, GB), Dedhiya; Mahendra G. (Pomona, NY)
Assignee:
Application Number:14/180,656
Patent Claim Types:
see list of patent claims
Use; Compound; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,969,566

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,829,191Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
9,695,122Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
9,284,314Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,969,566

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office2721005► Subscribe
Spain2560404► Subscribe
Hong Kong1196615► Subscribe
Israel229815► Subscribe
Japan2014517027► Subscribe
Japan6023800► Subscribe
Japan2017036307► Subscribe
China105294690► Subscribe
South Korea20140040748► Subscribe
Mexico2013014114► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
UBS
Accenture
Argus Health
AstraZeneca
Boehringer Ingelheim
Cipla
Colorcon
Express Scripts
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot